Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters











Database
Language
Publication year range
1.
Int J Mol Sci ; 25(15)2024 Jul 24.
Article in English | MEDLINE | ID: mdl-39125644

ABSTRACT

Spinocerebellar ataxia type 3 (SCA3) is the most common type of disease related to poly-glutamine (polyQ) repeats. Its hallmark pathology is related to the abnormal accumulation of ataxin 3 with a longer polyQ tract (polyQ-ATXN3). However, there are other mechanisms related to SCA3 progression that require identifying trait and state biomarkers for a more accurate diagnosis and prognosis. Moreover, the identification of potential pharmacodynamic targets and assessment of therapeutic efficacy necessitates valid biomarker profiles. The aim of this review was to identify potential trait and state biomarkers and their potential value in clinical trials. Our results show that, in SCA3, there are different fluid biomarkers involved in neurodegeneration, oxidative stress, metabolism, miRNA and novel genes. However, neurofilament light chain NfL and polyQ-ATXN3 stand out as the most prevalent in body fluids and SCA3 stages. A heterogeneity analysis of NfL revealed that it may be a valuable state biomarker, particularly when measured in plasma. Nonetheless, since it could be a more beneficial approach to tracking SCA3 progression and clinical trial efficacy, it is more convenient to perform a biomarker profile evaluation than to rely on only one.


Subject(s)
Biomarkers , Machado-Joseph Disease , Humans , Machado-Joseph Disease/genetics , Machado-Joseph Disease/metabolism , Machado-Joseph Disease/pathology , Ataxin-3/genetics , Ataxin-3/metabolism , Neurofilament Proteins/metabolism , Peptides/metabolism , Disease Progression , Oxidative Stress
2.
Parkinsonism Relat Disord ; 75: 27-29, 2020 06.
Article in English | MEDLINE | ID: mdl-32447234

ABSTRACT

To help address the scarcity of studies on the genetics of Parkinson's disease (PD) in Latin America, we screened 426 Ecuadorians with PD and 80 Colombians (PD = 55, Control = 26) for mutations within several PD-related genes. Among Colombians, we identified several variants within PARKIN and PINK1 genes.


Subject(s)
Parkinson Disease/genetics , Aged , Aged, 80 and over , Colombia , Ecuador , Female , Humans , Male , Middle Aged , Protein Kinases/genetics , Ubiquitin-Protein Ligases/genetics
3.
Parkinsonism Relat Disord ; 73: 16-18, 2020 04.
Article in English | MEDLINE | ID: mdl-32197197

ABSTRACT

We aimed to replicate a recent study that found a high frequency of the GBA p.K198E mutant in Colombian patients with PD. We identified the p.K198E substitution at a lower frequency in our cohort of Colombians with PD (2.1%), and this was not significantly different than controls (1.7%, P = 0.86) emphasizing the need for larger genetic studies in Latin America.


Subject(s)
Glucosylceramidase/genetics , Hispanic or Latino/genetics , Parkinson Disease/genetics , Adult , Aged , Aged, 80 and over , Colombia/ethnology , Female , Humans , Male , Middle Aged , Mutation , Parkinson Disease/ethnology , United States/ethnology
4.
Parkinsonism Relat Disord ; 41: 14-24, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28625595

ABSTRACT

Perry syndrome (PS) is a rare hereditary neurodegenerative disease characterized by autosomal dominant parkinsonism, psychiatric symptoms, weight loss, central hypoventilation, and distinct TDP-43 pathology. The mutated causative gene for PS is DCTN1, which encodes the dynactin subunit p150Glued. Dynactin is a motor protein involved in axonal transport; the p150Glued subunit has a critical role in the overall function. Since the discovery of DCTN1 in PS, it has been increasingly recognized that DCTN1 mutations can exhibit more diverse phenotypes than previously thought. Progressive supranuclear palsy- and/or frontotemporal dementia-like phenotypes have been associated with the PS phenotypes. In addition, DCTN1 mutations were identified in a family with motor-neuron disease before the discovery in PS. In this review, we analyze the clinical and genetic aspects of DCTN1-related neurodegeneration and discuss its pathogenesis. We also describe three families with PS, Canadian, Polish, and Brazilian. DCTN1 mutation was newly identified in two of them, the Canadian and Polish families. The Canadian family was first described in late 1970's but was never genetically tested. We recently had the opportunity to evaluate this family and to test the gene status of an affected family member. The Polish family is newly identified and is the first PS family in Poland. Although still rare, DCTN1-related neurodegeneration needs to be considered in a differential diagnosis of parkinsonian disorders, frontotemporal dementia, and motor-neuron diseases, especially if there is family history.


Subject(s)
Dynactin Complex/genetics , Hypoventilation/genetics , Mutation/genetics , Neurodegenerative Diseases/genetics , Parkinsonian Disorders/genetics , Brazil , Canada , Depression/genetics , Depression/pathology , Family Health , Female , Genetic Predisposition to Disease , Humans , Hypoventilation/pathology , Male , Parkinsonian Disorders/pathology , Phenotype , Poland
5.
Parkinsonism Relat Disord ; 20(8): 884-8, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24881494

ABSTRACT

OBJECTIVES: Perry syndrome consists of autosomal dominant Parkinsonism, depression, weight loss, and central hypoventilation. Eight mutations in 16 families have been reported: p.F52L, p.G67D, p.G71R, p.G71E, p.G71A, p.T72P, p.Q74P, and p.Y78C located in exon 2 of the dynactin 1 (DCTN1) gene on chromosome 2p13.1. METHODS: Genealogical, clinical, genetic, and functional studies were performed in three kindreds from New Zealand, the United States, and Colombia. A diaphragmatic pacemaker was implanted in the proband from the Colombian family to treat her respiratory insufficiency. Dopaminergic therapy was initiated in probands from two families. RESULTS: Besides the probands, 17 symptomatic relatives from all families were identified. The cardinal signs of Perry syndrome were present in all three probands with symptomatic disease onset in their fifth or sixth decade of life. Parkinsonism was moderate with a partial response to dopaminergic treatment. All affected persons but two died of respiratory insufficiency. The proband from the Colombian family is alive most likely due to early diagnosis and implantation of a diaphragmatic pacemaker. Two-and-a-half-year follow-up examination has revealed that the diaphragmatic pacemaker is optimally functioning without any major complications. In the Colombian and US families, the DCTN1 p.G71R and in the New Zealand family the DCTN1 p.Y78C mutations were identified. In functional assays, both mutations altered microtubule binding consistent with a pathogenic role. CONCLUSIONS: Perry syndrome is a rare condition, but new cases are expected to be diagnosed worldwide. Early diagnosis prevents life-threatening acute respiratory failure. Diaphragmatic pacemakers should be considered as an effective symptomatic treatment option.


Subject(s)
Hypoventilation/epidemiology , Hypoventilation/genetics , Parkinsonian Disorders/epidemiology , Parkinsonian Disorders/genetics , Colombia , Depression/epidemiology , Depression/genetics , Depression/therapy , Diaphragm/surgery , Dynactin Complex , Electrodes, Implanted , Female , Humans , Hypoventilation/therapy , Male , Microtubule-Associated Proteins/genetics , Middle Aged , Mutation , New Zealand , Parkinsonian Disorders/therapy , Pedigree , United States
SELECTION OF CITATIONS
SEARCH DETAIL